In a world where cancer continues to be a formidable adversary, a revolutionary treatment known as cellular immunotherapy is offering new hope to patients battling multiple myeloma. However, with a price tag of half a million dollars, this life-saving therapy remains out of reach for many. A clinical trial at Ben Taub Hospital in Houston, TX wants to change that, proving the treatment’s efficacy and potentially paving the way for more accessible care.
Doctors Martha Mims and Premal Lulla are at the forefront of this groundbreaking clinical trial. Dr. Lulla explains the process to KPRC 2 Click2Houston: “We take out T-cells from patients. We, in some way, train them to go after the cancer cells and then infuse them back to the patients.” This innovative approach, known as CAR T-cell therapy, has shown promising results, prompting the researchers to expand their study.
The choice of Ben Taub Hospital for this expansion was deliberate. Dr. Mims explains, “Our patients don’t have the same access to care that all the other patients in the community have.” This disparity in healthcare access is a crucial issue that the trial aims to address.
You May Also Like
Multiple myeloma, the focus of this study, is a particularly devastating form of blood cancer that primarily affects Black people. Dr. Mims describes its effects: “These patients have problems with their bones because the tumor can eat away at their bones, their calcium levels. The antibodies can cause problems with their kidneys, a whole host of problems.”
Two patients, Zella Duckworth and Javier Perez, shared their experiences with the treatment. Both had exhausted other options and were suffering from painful symptoms. Perez recounted, “I’ve had the bone infection…it was out of control. I mean, what it’s doing, just weeping and weeping, you know, twenty-four seven, from weeping fluid.” Duckworth, a Black patient, described her condition before the treatment: “My back and my whole body just in pain. I could barely walk.”
For these patients, the clinical trial was a last resort. Duckworth said, “I had two options. And I choose this. I said, well, I’ll try the trial because I didn’t wanna do the other.” The desperation in their voices is palpable, highlighting the critical need for accessible, effective treatments.
The results of the trial have been nothing short of miraculous. Both patients saw dramatic improvements after just one injection of the modified T-cells. Dr. Mims told Duckworth, “Your labs look great. And your last bone marrow exam was completely normal, which is good.” Perez confirmed, “They don’t see it anymore. Really? I’ve had test after test, and they don’t see it anymore.”
The emotional impact of this recovery is profound. When asked how it feels, Duckworth simply said, “Wonderful. Wonderful.” Perez echoed this sentiment, expressing amazement at how quickly he felt better: “That’s why I was like, wow. I forgot how it felt to be normal.”
However, the elephant in the room remains the sky-high cost of this treatment. Dr. Lulla stated, “It’s a one-time treatment, and it is about half a million dollars.” This price tag puts the therapy out of reach for many patients, especially those who are uninsured or underinsured.
Dr. Mims acknowledged this challenge: “We do the best we can without that therapy, but it’s better to have it, obviously. We’re trying to move forward. We’re trying to be sure that everyone in our community has the same access.”
There is some hope on the horizon. Dr. Lulla noted, “The good news is health insurance will pay for it because it’s FDA approved.” However, for those without adequate insurance, the situation remains dire. He added, “It is for that gap patients where you don’t have insurance or underinsured where programs like an expanded access program that the company will bear the cost of it would be helpful.”
Some pharma companies are already taking steps to address this issue. Dr. Lulla mentioned, “One of the companies that makes a CAR T-cell product does offer it to patients who don’t have health insurance and will cover the cost of the drug.” He hopes this will set a precedent: “My hope is that more companies will look upon that as an example and say, okay. Well, we know that there are patients who could be cured with this therapeutic, and we want to offer it to everybody.”
The impact of this treatment on patients’ lives is priceless. Duckworth, who once struggled to walk, now says, “I’m back going to the gym. I’m back walking. I’m back doing better. I don’t look like what I’ve been through.”
Looking to the future, the Ben Taub team plans to expand their trials to include lymphoma and leukemia patients. Their goal is clear: to make these cutting-edge treatments accessible to all patients, regardless of their financial situation.
This story serves as a powerful reminder of the potential of medical research to change lives. It also highlights the ongoing challenge of ensuring that these life-saving treatments are available to all who need them, not just those who can afford them. As Dr. Lulla concludes, “In that way, the access can broaden, which is really our goal.”
